Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Top Cited Papers
- 16 April 2013
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (6), 552-562
- https://doi.org/10.1016/s1470-2045(13)70093-7
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 20 references indexed in Scilit:
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid TumorsClinical Cancer Research, 2011
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI Journal of the National Cancer Institute, 2011
- Phase 3 trial of everolimus for metastatic renal cell carcinomaCancer, 2010
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free SurvivalJNCI Journal of the National Cancer Institute, 2009
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000